Cargando…
NSI‐189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats
Enhancing neurogenesis may be a powerful stroke therapy. Here, we tested in a rat model of ischemic stroke the beneficial effects of NSI‐189, an orally active, new molecular entity (mol. wt. 366) with enhanced neurogenic activity, and indicated as an anti‐depressant drug in a clinical trial (Fava et...
Autores principales: | Tajiri, Naoki, Quach, David M., Kaneko, Yuji, Wu, Stephanie, Lee, David, Lam, Tina, Hayama, Ken L., Hazel, Thomas G., Johe, Karl, Wu, Michael C., Borlongan, Cesar V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518191/ https://www.ncbi.nlm.nih.gov/pubmed/28181668 http://dx.doi.org/10.1002/jcp.25847 |
Ejemplares similares
-
Behavioral and Histopathological Assessment of Adult Ischemic Rat Brains after Intracerebral Transplantation of NSI-566RSC Cell Lines
por: Tajiri, Naoki, et al.
Publicado: (2014) -
Enhancement of Mitochondrial Function by the Neurogenic Molecule NSI-189 Accompanies Reversal of Peripheral Neuropathy and Memory Impairment in a Rat Model of Type 2 Diabetes
por: Jolivalt, C. G., et al.
Publicado: (2022) -
A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder
por: Papakostas, G. I., et al.
Publicado: (2019) -
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients
por: Fava, M, et al.
Publicado: (2016) -
Erratum: A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients
por: Fava, M, et al.
Publicado: (2016)